How Managed Access Programs Really Work: The Role of BAP Pharma Behind the Scenes
From the outside, a Managed Access Program can look deceptively simple. A patient needs treatment. A physician makes a request. Medicine is supplied. In reality, every successful access program is supported by a complex network of people, processes, and decisions working quietly in the background. This is why pharmaceutical and biotech companies partner with BAP […]
The Rare Disease Access Gap – Why Operational Readiness is Becoming the New Barrier to Treatment
For years, Rare Disease Access has been defined by three critical questions: Does a treatment exist? Is it approved? Will it be funded? Today, those questions remain important, but they no longer tell the whole story. Advances in genomics, new-born screening and rare disease regulation are enabling patients to be identified earlier than ever before. […]
Why are people with EDS and HSD receiving such late access to innovative therapies?
The Ehlers-Danlos Society – Why are people with EDS and HSD receiving such late access to innovative therapies? What is Ehlers-Danlos syndrome and hypermobility spectrum disorders? The Ehlers-Danlos syndromes are a group of heritable connective tissue disorders. Each type is caused by genetic variants that prevent connective tissue from functioning properly. Twelve types of EDS […]
Managed Access Program: A practical guide
Managed Access Programs are a key pillar of the drug development lifecycle, yet they remain widely misunderstood – both by the people who need them most and those trying to implement them. Part of the reason for this is language. There are many overlapping and inconsistently used terms in this field, which can confuse both […]
Partnering to Empower Patients: A Collaboration with Rare Beacon on Early Access Programs
How It Started One of our key focuses at BAP Pharma is to actively engage with patient advocacy groups (PAGs), particularly in the rare disease space. As part of our mission to support access to unlicensed medicines, we believe it’s essential to raise awareness about early access, compassionate use, and post-trial access programs – and […]
The Power of Collaboration: Why the Success of an Early Access Program Depends on Stakeholder Engagement
Early Access Programs (EAPs) offer a critical pathway for patients with serious or life-threatening conditions to access potentially life-saving treatments before they become commercially available. While these programs hold enormous promise, their success is never the result of one single effort. They depend on the collaboration of a wide range of stakeholders – from regulatory […]
Importing an Unlicensed Medicine
A US based biotechnology company approached BAP Pharma to enquire about providing life-saving early access to a promising two drug treatment that was undergoing phase II trials.
Delivering Urgent Named Patient Access Across Borders
An urgent request was received by BAP Pharma in December of 2020 from a multinational healthcare company, for assistance in gaining access to an unlicensed medicine for a 4-month-old critical patient in India.
Exclusive Agreement For The Supply and Distribution Of Bicillin® LA
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.